Equity down 38.7% to NZ$9.6m as NZ$1.0m convertible note debuts

Total assets fell to NZ$11.0m, at the lower edge of the supplied historical range (three-period mean NZ$14.6m), and total equity dropped 38.7% to NZ$9.6m. Total liabilities expanded 477.8% to NZ$1.4m, driven by a new NZ$1.0m convertible note that was not disclosed in the prior comparable balance sheet.

Operating activity remains immaterial in absolute terms. Revenue fell 40.5% to NZ$0.4m, the net loss widened 26.6% to NZ$0.7m, and operating cash outflow of NZ$0.5m was essentially unchanged on the prior comparable. Cash and equivalents finished broadly flat at NZ$1.0m.

The NZ$1.0m convertible note is the first interest-bearing instrument on the disclosed period-set balance sheet, and the release explicitly flags a rights issue opening in mid-January to "progress Talisman towards the profitable production of gold." Equity has fallen NZ$6.1m year-on-year against a disclosed half-year loss of only NZ$0.7m, leaving a material gap that the excerpts do not reconcile.

Cash runway is tight relative to plan. Cash of NZ$1.0m sits against a half-yearly operating burn of around NZ$0.5m before any pre-production capex. The cushion covers roughly two reporting halves at the current run rate, which means the convertible note and the January rights issue are not optional — they are funding management's stated intention to begin gold production in H2.

Operating metrics are not yet a meaningful read. Revenue of NZ$0.4m and a NZ$0.7m loss reflect exploration and incidental sales, not commercial production. ROE of -6.9% sits inside Annolyse's historical baseline (three-period mean -6.5%), so the loss itself is not the news; the funding plan and project timing are.

Management states an intention to "produce gold and generate revenues in the second half" and to open a rights issue in mid-January, but neither the dollar size of the raise nor the gold volumes are disclosed.

The supplied HY22→FY22 shape implies a prior-year H2 loss of around NZ$0.5m — similar to the HY22 first-half loss — but that is historic and tells us little about the current half once production spend ramps. Without stated targets, the next genuine read will come from the rights issue terms, the convertible note's conversion mechanics, and whether commercial gold sales actually emerge in H2.

Revenue is incidental, costs are exploration and overhead in character, and operating cash flow tracks the loss closely (NZ$0.5m outflow against the NZ$0.7m loss), so there is no working-capital tailwind or accrual benefit flattering the reported result. The pre-revenue setting also means the PBT growth observation flagged outside the historical baseline is a data artefact of zero values rather than an operating signal.

The balance-sheet read is where the real quality issue sits. A NZ$6.1m equity decline against a NZ$0.7m half-year loss — and roughly NZ$1.2m of trailing twelve-month losses on the supplied figures — leaves several million dollars unexplained from the excerpts available. Possible drivers include reserve adjustments, write-downs, or prior-period restatement, but the release does not identify a cause. Until that gap is reconciled, the integrity of reported equity cannot be independently confirmed, and the new NZ$1.0m convertible note adds claim seniority over an asset base already at the lower edge of its historical range.

This briefing cannot assess the technical readiness of the Talisman project, the terms of the proposed capital raises, or the underlying drivers of the equity decline beyond what the release excerpts disclose.